SCHEDULE: Janus Henderson Discloses 12.1% Stake in Enanta Pharma

Janus Henderson Group PLC and its affiliates have reported a significant beneficial ownership stake of 12.1% in Enanta Pharmaceuticals Inc.

Summary

• Janus Henderson Group PLC, a Jersey-based entity, beneficially owns 3,494,068 shares of Enanta Pharmaceuticals Inc. Common Stock, representing 12.1% of the class.
• Janus Henderson Biotech Innovation Master Fund Ltd, a Massachusetts-based entity and an indirect subsidiary of Janus Henderson, beneficially owns 2,959,525 shares, representing 10.6% of the class.
• Both reporting persons hold shared voting and shared dispositive power over their respective shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Enanta Pharmaceuticals Inc.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain subjective language or performance metrics, resulting in a neutral sentiment.

Future Outlook

NA

Industry Context

This filing indicates significant institutional interest in Enanta Pharmaceuticals, a biotechnology company. Large institutional holdings can signal confidence in a company's long-term prospects within the competitive biotech sector.

Stakeholder Impact

• Shareholders may view the significant institutional ownership by Janus Henderson as a positive indicator of confidence in Enanta Pharmaceuticals' value and future prospects.

Key Dates

Keywords

Enanta Pharmaceuticals, Janus Henderson Group, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Biotech